

FIRM / AFFILIATE OFFICES

Austin	Milan
Beijing	Munich
Boston	New York
Brussels	Orange County
Century City	Paris
Chicago	Riyadh
Dubai	San Diego
Düsseldorf	San Francisco
Frankfurt	Seoul
Hamburg	Shanghai
Hong Kong	Silicon Valley
Houston	Singapore
London	Tel Aviv
Los Angeles	Tokyo
Madrid	Washington, D.C.

August 25, 2023

**VIA EDGAR**

United States Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549-6010

Attention: Eric Atallah  
Al Pavot  
Daniel Crawford  
Laura Crotty

**Re: Neumora Therapeutics, Inc.**  
**Amendment No. 9 to Draft Registration Statement on Form S-1**  
**Submitted August 9, 2023**  
**CIK No. 0001885522**

Ladies and Gentlemen:

On behalf of our client, Neumora Therapeutics, Inc. (the "**Company**"), we are hereby filing with the Securities and Exchange Commission (the "**Commission**") the Company's Registration Statement on Form S-1 (the "**Registration Statement**"). The Company previously submitted a draft registration statement on Form S-1 on a confidential basis pursuant to Title I, Section 106 under the Jumpstart Our Business Startups Act on November 8, 2021 (the "**Draft Submission**"), which was amended by Amendment No. 1 to the Draft Submission confidentially submitted by the Company to the Commission on December 23, 2021 ("**Submission No. 2**"), Amendment No. 2 to the Draft Submission confidentially submitted by the Company to the Commission on February 11, 2022 ("**Submission No. 3**"), Amendment No. 3 to the Draft Submission confidentially submitted by the Company to the Commission on May 2, 2022 ("**Submission No. 4**"), Amendment No. 4 to the Draft Submission confidentially submitted by the

**LATHAM & WATKINS** LLP

Company to the Commission on June 10, 2022 (“**Submission No. 5**”), Amendment No. 5 to the Draft Submission confidentially submitted by the Company to the Commission on September 2, 2022 (“**Submission No. 6**”), Amendment No. 6 to the Draft Submission confidentially submitted by the Company to the Commission on May 2, 2023 (“**Submission No. 7**”), Amendment No. 7 to the Draft Submission confidentially submitted by the Company to the Commission on June 30, 2023 (“**Submission No. 8**”), and Amendment No. 8 to the Draft Submission confidentially submitted by the Company to the Commission on August 9, 2023 (“**Submission No. 9**”). The Registration Statement has been revised to reflect the Company’s responses to the comment letter to Submission No. 9 dated August 17, 2023 from the staff of the Commission (the “**Staff**”).

For ease of review, we have set forth below the numbered comment of your letter in bold type followed by the Company’s response thereto.

**Amendment No. 9 to Draft Registration Statement on Form S-1 submitted August 9, 2023**

**Prospectus Summary**

**Overview, page 1**

- 1. We note your statements throughout the prospectus that several of your programs target novel mechanisms of actions that “have shown preclinical and clinical validation” by Neumora and other leading biopharmaceutical companies. Please revise your disclosure to explain what you mean by “validation” and provide support for each statement. Please also ensure that this disclosure does not imply that approval by the FDA or similar regulatory bodies is assured, as such determination is not within the control of the company.**

*Response:* In response to the Staff’s comment, the Company has revised pages 2 and 116 of the Registration Statement.

\* \* \*

August 25, 2023

Page 3

**LATHAM & WATKINS** LLP

We hope the foregoing answers are responsive to your comments. Please do not hesitate to contact me by telephone at (415) 395-8216 or by email to Phillip.Stoup@lw.com with any questions or comments regarding this correspondence.

Very truly yours,

/s/ Phillip Stoup

Phillip Stoup  
of LATHAM & WATKINS LLP

cc: Henry O. Gosebruch, Neumora Therapeutics, Inc.  
Paul L. Berns, Neumora Therapeutics, Inc.  
Shayne Kennedy, Latham & Watkins LLP  
Charles S. Kim, Cooley LLP  
Kristin VanderPas, Cooley LLP  
Dave Peinsipp, Cooley LLP  
Denny Won, Cooley LLP